NovaBay Pharmaceuticals (NYSE:NBY) Now Covered by StockNews.com

StockNews.com assumed coverage on shares of NovaBay Pharmaceuticals (NYSE:NBY) in a research note published on Saturday. The firm issued a hold rating on the stock.

NovaBay Pharmaceuticals Stock Performance

NovaBay Pharmaceuticals stock opened at $0.59 on Friday. The stock has a market cap of $3.40 million, a PE ratio of -0.01 and a beta of 0.90. NovaBay Pharmaceuticals has a one year low of $0.36 and a one year high of $9.08. The stock has a fifty day moving average of $0.59 and a 200 day moving average of $0.62.

Insiders Place Their Bets

In other NovaBay Pharmaceuticals news, major shareholder Poplar Point Capital Partners bought 70,685 shares of the firm’s stock in a transaction that occurred on Friday, January 31st. The shares were bought at an average price of $0.65 per share, with a total value of $45,945.25. Following the purchase, the insider now owns 620,685 shares of the company’s stock, valued at $403,445.25. This trade represents a 12.85 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Insiders purchased a total of 269,374 shares of company stock worth $167,103 over the last quarter. 0.10% of the stock is currently owned by corporate insiders.

NovaBay Pharmaceuticals Company Profile

NovaBay Pharmaceuticals, Inc, a biopharmaceutical company, develops and sells eyecare, skincare, and wound care products in the United States and internationally. It offers Avenova Spray, a solution for removing foreign materials, including microorganisms and debris from skin around the eye, such as the eyelid; and wound care products, which are used for cleansing and irrigation as part of surgical procedures, as well as treating certain wounds, burns, ulcers, and other injuries under the NeutroPhase and PhaseOne brands.